How has proteomics informed transfusion biology so far?

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 3, 2010, Pages 153-172

  Liumbruno, Giancarlo ^a,b   D'Alessandro, Angelo ^a,c   Grazzini, Giuliano ^a   Zolla, Lello ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF TUSCIA   (Italy)

Author keywords

Plasma; Plasma derivative products; Platelet; Proteomics; Red blood cell; Transfusion medicine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

BLOOD COMPONENT; BLOOD SAMPLING; BLOOD STORAGE; BLOOD TRANSFUSION; ERYTHROCYTE; GENOME ANALYSIS; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE; MOLECULAR BIOLOGY; PROTEOMICS; REVIEW; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; THROMBOCYTE;

ANIMALS; BLOOD COMPONENT TRANSFUSION; HUMANS; PROTEOMICS;

EID: 78049374198     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.009     Document Type: Review

References (215)

1. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
2. Subramanian G., Adams M.D., Venter J.C., Broder S. Implications of the human genome for understanding human biology and medicine. JAMA 2001, 286(18):2296-2307.
3. Stein L.D. Human genome: end of the beginning. Nature 2004, 431(7011):915-916.
4. Evans W.E., Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
5. Shah R.R. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005, 360(1460):1617-1638.
6. Nebert D.W., Zhang G., Vesell E.S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008, 40(2):187-224.
7. Mann K.G., Brummel-Ziedins K., Undas A., Butenas S. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost 2004, 2(10):1727-1734.
8. Wasinger V.C., Cordwell S.J., Cerpa-Poljak A., et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995, 16:1090-1094.
9. Marko-Varga G., Fehniger T.E. Proteomics and disease: the challenges for technology and discovery. J Proteome Res 2004, 3:167-178.
10. Rappsilber J., Mann M. What does it mean to identify a protein in proteomics?. Trends Biochem Sci 2002, 27:74-78.
11. Zhu H., Bilgin M., Snyder M. Proteomics. Annu Rev Biochem 2003, 72:783-812.
12. Calvo K.R., Liotta L.A., Petricoin E.F. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 2005, 25(1-2):107-125.
13. Unwin R.D., Whetton A.D. How will haematologists use proteomics?. Blood Rev 2007, 21(6):315-326.
14. Thadikkaran L., Siegenthaler M.A., Crettaz D., et al. Recent advances in blood-related proteomics. Proteomics 2005, 5:3019-3034.
15. Braziel R.M., Shipp M.A., Feldman A.L., et al. Molecular diagnostics. Hematol Am Soc Hematol Educ Program 2003, 1:279-293.
16. Wiltgen M., Tilz G.P. DNA microarray analysis: principles and clinical impact. Hematology 2007, 12(4):271-287.
17. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18(3-4):533-537.
18. Anderson N.L., Anderson N.G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 1998, 19(11):1853-1861.
19. Cristea I.M., Gaskell S.J., Whetton A.D. Proteomics techniques and their application to hematology. Blood 2004, 103:3624-3634.
20. de Hoog C.L., Mann M. Proteomics. Annu Rev Genomics Hum Genet 2004, 5:267-293.
21. Liumbruno G., D'Alessandro A., Grazzini G., Zolla L. Blood-related proteomics. J Proteomics 2009, 10.1016/j.jprot.2009.06.010.
22. Rees-Unwin K.S., Morgan G.J., Davies F.E. Proteomics and the haematologist. Clin Lab Haem 2004, 26:77-86.
23. Greinacher A., Warkentin T.E. Transfusion medicine in the era of genomics and proteomics. Transfus Med Rev 2005, 19:288-294.
24. Queloz P.A., Thadikkaran L., Crettaz D., Rossier J.S., Barelli S., Tissot J.D. Proteomics and transfusion medicine: future perspectives. Proteomics 2006, 6:5605-5614.
25. Page M.J., Griffiths T.A.M., Bleackley M.R., MacGillivray R.T.A. Proteomics: applications relevant to transfusion medicine. Transfus Med Rev 2006, 20:63-74.
26. Thiele T., Steil L., Völker U., Greinacher A. Proteomics of blood-based therapeutics. BioDrugs 2007, 21:179-193.
27. Liumbruno G.M. Proteomics: applications in transfusion medicine. Blood Transfus 2008, 6(2):70-85.
28. Liumbruno G., D'Amici G.M., Grazzini G., Zolla L. Transfusion medicine in the era of proteomics. J Proteomics 2008, 71(1):34-45.
29. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
30. Righetti P.G., Castagna A., Herbert B., Candiano G. How to bring the "unseen" proteome to the limelight via electrophoretic pre-fractionation techniques. Biosci Rep 2005, 25(1-2):3-17.
31. Pieper R., Gatlin C.L., Makusky A.J., et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3:1345-1364.
32. Echan L.A., Tang H.Y., Ali-Khan N., Lee K.B., Speicher D.W. Depletion of multiple high-abundance proteins improves the protein profiling capacities of human serum and plasma. Proteomics 2005, 5:3292-3303.
33. Heller M., Michel P.E., Morier P., et al. Two-stage off-gel isoelectric focusing: protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis 2005, 26(6):1174-1188.
34. Boschetti E., Righetti P.G. The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics 2009, 10.1002/pmic.200800389.
35. Zhou M., Lucas D.A., Chan K.C., et al. An investigation into the human serum interactome. Electrophoresis 2004, 25:1289-1298.
36. Granger J., Siddiqui J., Copeland S., Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5(18):4713-4718.
37. Yocum A.K., Yu K., Oe T., Blair I.A. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res 2005, 4(5):1722-1731.
38. Petricoin E.F., Belluco C., Araujo R.P., Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006, 6(12):961-967.
39. Atallah E., Schiffer C.A. Granulocyte transfusion. Curr Opin Hematol 2006, 13(1):45-49.
40. Peters C. Granulocyte transfusions in neutropenic patients: beneficial effects proven?. Vox Sang 2009, 96(4):275-283.
41. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005, 19(2):110-126.
42. De Rosa M.C., Carelli Alinovi C., Galtieri A., Scatena R., Giardina B. The plasma membrane of erythrocytes plays a fundamental role in the transport of oxygen, carbon dioxide and nitric oxide and in the maintenance of the reduced state of the heme iron. Gene 2007, 398:162-171.
43. Kooyman D.L., Byrne G.W., McClellan S., et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995, 269(5220):89-92.
44. Civenni G., Test S.T., Brodbeck U., Butikofer P. In vitro incorporation of GPI-anchored proteins into human erythrocytes and their fate in the membrane. Blood 1998, 91:1784-1792.
45. Schifferli J.A., Taylor R.P. Physiological and pathological aspects of circulating immune complexes. Kidney Int 1989, 35:993-1003.
46. Palis J. Ontogeny of erythropoiesis. Curr Opin Hematol 2008, 15(3):155-161.
47. Koury M.J., Sawyer S.T., Brandt S.J. New insights into erythropoiesis. Curr Opin Hematol 2002, 9(2):93-100.
48. Grazzini G. The Italian blood system. Blood Transfus 2009, 7(1):4-5.
49. Rosenblum B.B. Two-dimensional gel electrophoresis of erythrocyte membrane proteins. Prog Clin Biol Res 1981, 56:251-268.
50. Low T.Y., Seow T.K., Chung M.C. Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics 2002, 2:1229-1239.
51. Goodman S.R., Kurdia A., Ammann L., Kakhniashvili D., Daescu O. The human red blood cell proteome and interactome. Exp Biol Med (Maywood) 2007, 232:1391-1408.
52. Roux-Dalvai F., Gonzalez de Peredo A., Simó C., et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics 2008, 7(11):2254-2269.
53. Florens L., Liu X., Wang Y., et al. Proteomics approach reveals novel proteins on 5the surface of malaria-infected erythrocytes. Mol Biochem Parasitol 2004, 135:1-11.
54. Körbel S., Büchse T., Prietzsch H., et al. Phosphoprotein profiling of erythropoietin receptor-dependent pathways using different proteomic strategies. Proteomics 2005, 5(1):91-100.
55. Jiang M., Jia L., Jiang W., et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun 2003, 309:196-200.
56. Kakhniashvili D.G., Griko N.B., Bulla L.A., Goodman S.R. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med 2005, 230:787-792.
57. Chou J., Choudhary P.K., Goodman S.R. Protein profiling of sickle cell versus control RBC core membrane skeletons by ICAT technology and tandem mass spectrometry. Cell Mol Biol Lett 2006, 11(3):326-337.
58. Ghatpande S.S., Choudhary P.K., Quinn C.T., Goodman S.R. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome. Exp Biol Med 2008, 233(12):1510-1517.
59. Haynes J., Obiako B., Hester R.B., Baliga B.S., Stevens T. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol Heart Circ Physiol 2008, 294:H379-H385.
60. Prabakaran S., Wengenroth M., Lockstone H.E., Lilley K., Leweke F.M., Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 2007, 6(1):141-149.
61. Högman C.F., Meryman H.T. Red blood cells intended for transfusion: quality criteria revisited. Transfusion 2006, 46(1):137-142.
62. Novotny V.M. Red cell transfusion in medicine: future challenges. Transfus Clin Biol 2007, 14(6):538-541.
63. Klein H.G., Spahn D.R., Carson J.L. Red blood cell transfusion in clinical practice. Lancet 2007, 370(9585):415-426.
64. Hess J.R. An update on solutions for red cell storage. Vox Sang 2006, 91(1):13-19.
65. Hess J.R. Red cell freezing and its impact on the supply chain. Transfus Med 2004, 14(1):1-8.
66. Council of Europe Guide to the preparation, use and quality assurance of blood components. Recommendation no R (95) 15 on the preparation, use and quality assurance of blood components 2008, Council of Europe Press, Strasbourg. 14th ed.
67. Valeri C.R., Ragno G., Pivacek L.E., et al. An experiment with glycerol-frozen red blood cells stored at -80 degrees C for up to 37 years. Vox Sang 2000, 79(3):168-174.
68. Yoshida T., AuBuchon J.P., Tryzelaar L., Foster K.Y., Bitensky M.W. Extended storage of red blood cells under anaerobic conditions. Vox Sang 2007, 92(1):22-31.
69. Yoshida T., AuBuchon J.P., Dumont L.J., et al. The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells. Transfusion 2008, 48(10):2096-2105.
70. Dumont L.J., Yoshida T., AuBuchon J.P. Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery. Transfusion 2009, 49(3):458-464.
71. D'Amici G.M., Rinalducci S., Zolla L. Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res 2007, 6:3242-3255.
72. Messana I., Ferroni L., Misiti F., et al. Blood bank conditions and RBCs: the progressive loss of metabolic modulation. Transfusion 2000, 40(3):353-360.
73. Annis A.M., Glenister K.M., Killian J.J., Sparrow R.L. Proteomic analysis of supernatants of stored red blood cell products. Transfusion 2005, 45:1426-1433.
74. Bosman G.J., Lasonder E., Luten M., Roerdinkholder-Stoelwinder B., Novotnyó V.M., Bos H., et al. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion 2008, 48(5):827-835.
75. Schenk B.I., Petersen F., Flad H.D., Brandt E. Platelet-derived chemokines CXC chemokine ligand (CXC)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol 2002, 169:2602-2610.
76. Sparrow R.L., Patton K.A. Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion 2004, 44:722-773.
77. Annis A.M., Sparrow R.L. Storage duration and white blood cell content of red blood cell (RBC) products increases adhesion of stored RBCs to endothelium under flow conditions. Transfusion 2006, 46:1561-1567.
78. Greenwalt T.J. The how and why of exocytic vesicles. Transfusion 2006, 46:143-152.
79. Bosman G.J., Werre J.M., Willekens F.L., Novotný V.M. Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion. Transfus Med 2008, 18(6):335-347.
80. D'Alessandro A., Righetti P.G., Zolla L. The red blood cell proteome and interactome: an update. J Proteome Res 2009, 10.1021/pr900831f.
81. Patel S.R., Hartwig J.H., Italiano J.E. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005, 115:3348-3354.
82. Li J., Xia Y., Bertino A.M., Coburn J.P., Kuter D.J. The mechanism of apoptosis in human platelets during storage. Transfusion 2000, 40(11):1320-1329.
83. White J.G. Electron microscopic studies of platelet secretion. Prog Hemostasis Thromb 1974, 2:49-98.
84. White J.G. Interaction of membrane systems in blood platelets. Am J Pathol 1972, 66:295-312.
85. Cutler L., Rodan G., Feinstein M.B. Cytochemical localization of adenylate cyclase and of calcium ion, magnesium ion-activated ATPases in the dense tubular system of human blood platelets. Biochim Biophys Acta 1978, 542:357-371.
86. McRedmond J.P., Park S.D., Reilly D.F. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004, 3:133-144.
87. Gnatenko D.V., Dunn J.J., McCorkle S.R. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003, 101:2285-2293.
88. Weyrich A.S., Lindemann S., Tolley N.D. Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost 2004, 30:491-498.
89. Gailani D., Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007, 27:2507-2513.
90. Kolev K., Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003, 89:610-621.
91. Clemetson K.J., Capitanio A., Lüscher E.F. High resolution two-dimensional gel electrophoresis of the proteins and glycoproteins of human blood platelets and platelet membranes. Biochim Biophys Acta 1979, 553:11-24.
92. Gravel P., Sanchez J.C., Walzer C., et al. Human blood platelet protein map established by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1995, 16:1152-1159.
93. Moebius J., Zahedi R.P., Lewandrowski U., Berger C., Walter U., Sickmann A. The human platelet membrane proteome reveals several new potential membrane proteins. Mol Cell Proteomics 2005, 4(11):1754-1761.
94. Guerrier L., Claverol S., Fortis F., et al. Exploring the platelet proteome via combinatorial, hexapeptide ligand libraries. J Proteome Res 2007, 6(11):4290-4303.
95. O'Neill E.E., Brock C.J., von Kriegsheim A.F., et al. Towards complete analysis of the platelet proteome. Proteomics 2002, 2:288-305.
96. García A., Prabhakar S., Brock C.J., et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004, 4:656-668.
97. Claeys D., Geering K., Meyer B.J. Two-dimensional Blue Native/sodium dodecyl sulfate gel electrophoresis for analysis of multimeric proteins in platelets. Electrophoresis 2005, 26:1189-1199.
98. Immler D., Gremm D., Kirsch D., Spengler B., Presek P., Meyer H.E. Identification of phosphorylated proteins from thrombin-activated human platelets isolated by two-dimensional gel electrophoresis by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) and liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). Electrophoresis 1998, 19(6):1015-1023.
99. Marcus K., Immler D., Sternberger J., Meyer H.E. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 2000, 21(13):2622-2636.
100. Marcus K., Moebius J., Meyer H.E. Differential analysis of phosphorylated proteins in resting and thrombin-stimulated human platelets. Anal Bioanal Chem 2003, 376(7):973-993.
101. Maguire P.B., Wynne K.J., Harney D.F., O'Donoghue N.M., Stephens G., Fitzgerald D.J. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics 2002, 2(6):642-648.
102. García A., Prabhakar S., Hughan S., et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 2004, 103(6):2088-2095.
103. García A., Senis Y.A., Antrobus R., et al. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics 2006, 6(19):5332-5343.
104. Lewandrowski U., Moebius J., Walter U., Sickmann A. Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach. Mol Cell Proteomics 2006, 5(2):226-233.
105. Coppinger J.A., Cagney G., Toomey S., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103(6):2096-2104.
106. Slichter S.J. Controversies in platelet transfusion therapy. Annu Rev Med 1980, 31:509-540.
107. Higby D.J., Cohen E., Holland J.F., Sinks S. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974, 14:440-446.
108. Holme S., Vaidja K., Murphy S. Platelet storage at 22°C: effect of type of agitation on morphology, viability, and function in vitro. Blood 1978, 52:425-435.
109. Blajchman M.A. Incidence and significance of the bacterial contamination of blood components. Dev Biol 2002, 108:59-67.
110. Hillyer C.D., Josephson C.D., Blajchman M.A., Vostal J.G., Epstein J.S., Goodman J.L. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program 2003, 1:575-589.
111. Ben-Hur E., Moor A.C.E., Margolis-Nunno H., et al. The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Transfus Med Rev 1996, 10:15-22.
112. Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Transfus Med Rev 1999, 13:18-30.
113. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang 2000, 78(2):203-204.
114. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000, 78(2):211-215.
115. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
116. Klinger M.H. The storage lesions of platelets: ultrastructural and functional aspects. Ann Hematol 1996, 73:103-112.
117. Seghatchian J., Krailadsiri P. The platelet storage lesion. Transfus Med Rev 1997, 11:130-144.
118. Cardigan R., Turner C., Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005, 88:153-163.
119. Snyder E.L., Dunn B.E., Giometti C.S., et al. Protein changes occurring during storage of platelet concentrates. A two-dimensional gel electrophoresis analysis. Transfusion 1987, 27:335-341.
120. Thiele T., Steil L., Gebhard S., et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007, 47:1221-1233.
121. Glenister K.M., Payne K.A., Sparrow R.L. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage. Transfusion 2008, 48:99-107.
122. Wurtz V., Hechler B., Ohlmann P., et al. Identification of platelet factor 4 and β-thromboglobulin by profiling and liquid chromatography tandem mass spectrometry of supernatant peptides in stored apheresis and buffy-coat platelet concentrates. Transfusion 2007, 47:1099-1100. [letter].
123. Maynard D.M., Heijnen H.F., Horne M.K., White J.G., Gahl W.A. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost 2007, 5(September (9)):1945-1955.
124. Albanyan A.M., Murphy M.F., Rasmussen J.T., Heegaard C.W., Harrison P. Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: a comparison study with annexin V. Transfusion 2009, 49(1):99-107.
125. Ryu S.W., Suh I.B., Cho Y. Protein profile changes in platelet concentrates according to storage and leukoreduction-analysis using proteomics technology. Korean J Lab Med 2008, 28(1):53-63.
126. Thon J.N., Schubert P., Duguay M., et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion 2008, 48(3):425-435.
127. Springer D., Miller J., Spinelli S., et al. Platelet proteome changes associated with diabetes and during platelet storage for transfusion. J Proteome Res 2009, doi:10.1021/pr800885j.
128. Sacristan D., Marques M., Zamorano-Leon J.J., et al. Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin Appl 2008, 2:1300-1312.
129. Garritsen H.S., Fan A.X., Bosse N., et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens. Transfusion 2009, 49(2):252-258.
130. Kroll H., Yates J., Santoso S. Immunization against a lowfrequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele specific cell lines expressing recombinant antigens. Transfusion 2005, 45:353-358.
131. Kaplan C. Neonatal alloimmune thrombocytopenia: a 50-year story. Immunohematology 2007, 23:9-13.
132. Rosenberg N., Dardik R. Post-transfusion purpura-when and why?. Isr Med Assoc J 2006, 8:709-710.
133. Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007, 23:20-33.
134. Wu Y.Y., Csako G. Rapid and/or high-throughput genotyping for human red blood cell, platelet and leukocyte antigens, and forensic applications. Clin Chim Acta 2006, 363(1-2):165-176.
135. Fountoulakis M., Juranville J.F., Jiang L., et al. Depletion of the high-abundance plasma proteins. Amino Acids 2004, 27(3-4):249-259.
136. Tiselius A. Electrophoresis of serum globulin, I. Biochem J 1937, 31(2):313-317.
137. Anderson L., Anderson N.G. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci USA 1977, 74:5421-5425.
138. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250(10):4007-4021.
139. Tracy R.P., Currie R.M., Young D.S. Two-dimensional gel electrophoresis of serum specimens from a normal population. Clin Chem 1982, 28(4;2):890-899.
140. Harrison H., Miller K., Ober C., Refetoff S., Dick M., Elias S. Identification of a serum protein polymorphism via two-dimensional electrophoresis. Family and population studies in two genetically isolated groups: North American Hutterites and Australian aborigines. Am J Hum Genet 1991, 48(2):362-369.
141. Gravel P., Golaz O., Walzer C., Hochstrasser D.F., Turler H., Balant L.P. Analysis of glycoproteins separated by two-dimensional gel electrophoresis using lectin blotting revealed by chemiluminescence. Anal Biochem 1994, 221(1):66-71.
142. Henry H., Froehlich F., Perret R., et al. Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. Clin Chem 1999, 45(9):1408-1413.
143. Richter R., Schulz-Knappe P., Schrader M., et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl 1999, 726(1-2):25-35.
144. Omenn G.S., States D.J., Adamski M., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5(13):3226-3245.
145. Li X., Gong Y., Wang Y., et al. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 2005, 5(13):3423-3441.
146. Smalley D.M., Root K.E., Cho H., Ross M.M., Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007, 97(1):67-80.
147. Solheim B.G., Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006, 35:83-90.
148. Tissot J.D., Hochstrasser D.F., Schneider B., Morgenthaler J.J., Schneider P. No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high-resolution two-dimensional electrophoresis. Br J Haematol 1994, 86:143-146.
149. Wagner S.J., Cifone MA, Murli H., Dodd R.Y., Myhr B. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion 1995, 35:407-413.
150. AuBuchon J.P., Pickard C., Herschel L., O'Connor J.L., Lee E. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang 1998, 74:1-6.
151. Riggert J., Humpe A., Legler T.J., Wolf C., Simson G., Köhler M. Filtration of methylene blue-photo oxidized plasma: influence on coagulation and cellular contamination. Transfusion 2001, 41:82-86.
152. Crettaz D., Sensebe L., Vu D.H., et al. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics 2004, 4:881-891.
153. Steil L., Thiele T., Hammer E., et al. Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. Transfusion 2008, 48(11):2356-2363.
154. Qian W.J., Kaleta D.T., Petritis B.O., et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 2008, 7(10):1963-1973.
155. Schenk S., Schoenhals G.J., de Souza G., Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 2008, 1:41.
156. Zheng X., Wu S.L., Hincapie M., Hancock W.S. Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 2009, 10.1016/j.chroma.2009.01.063.
157. Muthusamy B, Hanumanthu G, Suresh S, Rekha B, Srinivas D, Karthick L, et al. Plasma Proteome Database as a resource for proteomics research. Proteomics 2005;5(13):3531-6. Available at: [last accessed on the 15th June 2009]. http://www.plasmaproteomedatabase.org/.
158. Omenn G.S., Aebersold R., Paik Y.K. 7(th) HUPO World Congress of Proteomics: launching the second phase of the HUPO Plasma Proteome Project (PPP-2) 16-20 August 2008, Amsterdam, The Netherlands. Proteomics 2009, 9(1):4-6.
159. Janzi M., Odling J., Pan-Hammarström Q., et al. Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics 2005, 4(12):1942-1947.
160. Gast M.C., Van Gils C.H., Wessels L.F., et al. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol Rep 2009, 22(1):205-213.
161. Schaub N.P., Jones K.J., Nyalwidhe J.O., et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 2009, 208(5):970-978.
162. Fiedler G.M., Leichtle A.B., Kase J., et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 2009, 15(11):3812-3819.
163. Lee N.P., Chen L., Lin M.C., et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 2009, 8(3):1293-1303.
164. Oh J.H., Lotan Y., Gurnani P., Rosenblatt K.P., Gao J. Prostate cancer biomarker discovery using high performance mass spectral serum profiling. Comput Methods Programs Biomed 2009, 10.1016/j.cmpb.2009.04.003.
165. Schwamborn K., Krieg R.C., Grosse J., et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009, 10.1016/j.eururo.2009.02.031.
166. Hübel K., Dale D.C., Liles W.C. Granulocyte transfusion therapy: update on potential clinical applications. Curr Opin Hematol 2001, 8:161-164.
167. Price T.H. Granulocyte transfusion: current status. Semin Hematol 2007, 44:15-23.
168. Hübel K., Rodger E., Gaviria J.M., et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion 2005, 45:1876-1889.
169. Italian Ministry of Health. Decree of March 3rd, 2005. Characteristics and modalities for blood and blood components donation. Gazzetta Ufficiale della Repubblica Italiana n. 85, April 13th, 2005.
170. Morris C.F., Castro M.S., Fontes W. Neutrophil proteome: lessons from different standpoints. Protein Pept Lett 2008, 15(9):995-1001.
171. Boussac M., Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000, 21:665-672.
172. Avram D., Romijn E.P., Pap E.H., Heck A.J., Wirtz K.W. Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack. A proteomic study using a tyrosylating fluorophore. Proteomics 2004, 4(8):2397-2407.
173. Lominadze G., Powell D.W., Luerman G.C., Link A.J., Ward R.A., McLeish K.R. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics 2005, 4(10):1503-1521.
174. Feuk-Lagerstedt E., Movitz C., Pellmé S., Dahlgren C., Karlsson A. Lipid raft proteome of the human neutrophil azurophil granule. Proteomics 2007, 7(2):194-205.
175. Füllekrug J., Simons K. Lipid rafts and apical membrane traffic. Ann NY Acad Sci 2004, 1014:164-169.
176. Razzaq T.M., Ozegbe P., Jury E.C., Sembi P., Blackwell N.M., Kabouridis P.S. Regulation of T-cell receptor signalling by membrane microdomains. Immunology 2004, 113(4):413-426.
177. Ministero del Lavoro, della Salute e delle Politiche Sociali. Uso appropriato delle cellule staminali del sangue del cordone ombelicale. Elementi informativi essenziali; 2009. Available at: [last accessed on the 26th of March 2009]. http://www.ministerosalute.it/imgs/C_17_primopianoNuovo_228_documenti_itemDocumenti_0_fileDocumento.pdf.
178. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
179. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004, 104:3813-3820.
180. Brand A., Rebulla P., Engelfriet C.P., et al. Cord blood banking. Vox Sang 2008, 95(4):335-348.
181. Koike K. Cryopreservation of pluripotent and committed hemopoietic progenitor cells from human bone marrow and cord blood. Acta Paediatr Jpn. 1983, 25:275.
182. Zenzmaier C., Kollroser M., Gesslbauer B., Jandrositz A., Preisegger K.H., Kungl A.J. Preliminary 2-D chromatographic investigation of the human stem cell proteome. Biochem Biophys Res Commun 2003, 310(2):483-490.
183. Zenzmaier C., Gesslbauer B., Grobuschek N., Jandrositz A., Preisegger K.H., Kungl A.J. Proteomic profiling of human stem cells derived from umbilical cord blood. Biochem Biophys Res Commun 2005, 328(4):968-972.
184. Wei Y.Q., Feng R., Yi Z.S., Liu Q.F. Establishment of two-dimensional gel electrophoresis profiles of proteome from CD34(+) hematopoietic stem/progenitor cells. Di Yi Jun Yi Da Xue Xue Bao 2003, 23(11):1161-1164.
185. Tao W., Wang M., Voss E.D., et al. Comparative proteomic analysis of human CD34+ stem/progenitor cells and mature CD15+ myeloid cells. Stem Cells 2004, 22(6):1003-1014.
186. Liu F., Lu J., Fan H.H., et al. Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome. Proteomics 2006, 6(9):2673-2692.
187. Unwin R.D., Smith D.L., Blinco D., et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 2006, 107(12):4687-4694.
188. D'Alessandro A., Liumbruno G., Grazzini G., Pupella S., Lombardini L., Zolla L. Umbilical cord blood stem cells: towards a proteomic approach. J Proteomics 2009, 10.1016/j.jprot.2009.06.009.
189. Theilgaard-Mönch K., Raaschou-Jensen K., Schjødt K., et al. Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts. Bone Marrow Transplant 2003, 32(12):1125-1133.
190. Kaiser T., Kamal H., Rank A., et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:340-349.
191. Weissinger E.M., Schiffer E., Hertenstein B., et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007, 109(12):5511-5519.
192. Wang H., Clouthier S.G., Galchev V., et al. Intactprotein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005, 4:618-625.
193. Imanguli M.M., Atkinson J.C., Harvey K.E., et al. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol 2007, 35:184-192.
194. Colquhoun D.R., Goldman L.R., Cole R.N., et al. Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environ Health Perspect 2009, 117(5):832-838.
195. Farrugia A., Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 2006, 19(1):243-258.
196. Burnouf T. Plasma fractionation in the world: current status. Transfus Clin Biol 2007, 14(1):41-50.
197. Brigulla M., Thiele T., Scharf C., et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion 2006, 46:377-385.
198. Liumbruno G., Bennardello F., Lattanzio A., Piccoli P. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009, 7:132-150.
199. Köhler M., Hellstern P., Lechler E., Uberfuhr P., Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998, 80:399-402.
200. Demelbauer U.M., Plematl A., Josic D., Allmaier G., Rizzi A. On the variation of glycosylation in human plasma derived antithrombin. J Chromatogr A 2005, 1080(1):15-21.
201. Plematl A., Demelbauer U.M., Josic D., Rizzi A. Determination of the site-specific and isoform-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC-ESI-MS/MS. Proteomics 2005, 5(15):4025-4033.
202. Kovac S., Yang X., Huang F., Hixson D., Josic D. Proteomics as a tool for optimization of human plasma protein separation. J Chromatogr A 2008, 1194(1):38-47.
203. Yang X., Clifton J., Huang F., Kovac S., Hixson D.C., Josic D. Proteomic analysis for process development and control of therapeutic protein separation from human plasma. Electrophoresis 2009, 30(7):1185-1193.
204. Eden E., Turino G.M. Alpha 1-antitrypsin deficiency: lessons from longevity. Chest 2009, 135(3):591-592.
205. Kanazawa S., Kinoshita Y., Nakagawa Y., et al. Pneumothorax associated with alpha1-antitrypsin deficiency. Intern Med 2009, 48(5):387-388.
206. Campos M.A., Alazemi S., Zhang G., Wanner A., Sandhaus R.A. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD 2009, 6(1):31-40.
207. Yu M., Wang X.X., Zhang F.R., et al. Proteomic analysis of the serum in patients with idiopathic pulmonary arterial hypertension. J Zhejiang Univ Sci B 2007, 8(4):221-227.
208. Mannucci P.M., Gringeri A., Peyvandi F., Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007, 13(5):65-68.
209. Righetti P.G., Boschetti E. Sherlock Holmes and the proteome-a detective story. FEBS J 2007, 274(4):897-905.
210. Herosimczyk A., Dejeans N., Sayd T., Ozgo M., Skrzypczak W.F., Mazur A. Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol 2006, 57(7):81-93.
211. Anstee D.J. Whatomics. Vox Sang 2004, 87(1):13-14.
212. Kitano H. Introductions to systems biology. Tanpakushitsu Kakusan Koso 2003, 48(7):789-793.
213. Friboulet A., Thomas D. Systems biology-an interdisciplinary approach. Biosens Bioelectron 2005, 20(12):2404-2407.
214. Liotta L.A., Petricoin E.F. Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008, 54(1):3-5.
215. Tissot J.D., Schneider P. Proteomics: biomedical and pharmaceutical applications 2004, 57-99. Kluwer Academic Publishers, Amsterdam. H. Hondermarck (Ed.).